Opt-80 Higher Cure and Lower Relapse Rates
According to TheStreet.com , top-line results of Optimer’s phase III Opt-80 study are demonstrating higher cure rates and lower relapse rates when compared to vancomycin.
Cure Rates Similar
If you ask me, the cure rates were similar (88% versus 86%), but this is still fantastic news. Currently, there are two antibiotics being widely used to treat C Diff: Vancomycin/Vancocin and Metronidazole/Flagyl. If the FDA approves Opt-80/PAR-101, there will be three that are widely used. With the increase in antibiotic resistant strains of C Diff being found this is could be huge. Think about the person who is battling C Diff right now and getting no response from either vancomycin or metronidazole. Now, they’ll have another chance with a new antibiotic that is being shown to be an effective cure for C Diff.
Even better news is that the study is showing that the relapse rates associated with Opt-80 are much lower than those associated with vancomycin (15% versus 25%). I, like so many of you who have emailed me, had great results with the existing antibiotics. However, it seemed that everytime I tapered off of the antibiotic, I would very quickly get the whole cycle started again with a new bout of C Diff. Here again, with Opt-80, I see great promise in having another antibiotic option that may prevent relapses for some people.